Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Angany Genetics, a biotechnology company, has plans to start its new production unit at the PharmaParc II activities park in Val-de-Reuil (Eure), France, in May 2013.
Subscribe to our email newsletter
Till now, the company has been using a prototype-scale production facility, but the new unit will enable industrial-scale production of a series of purified and optimised allergens.
The allergens include Der p 1 and Der p 2, which affect 80% of the patients with house dust mite allergies, and Der p 4 and Der p 7 affects patients with house-mite allergies.
Angany Genetics CEO Dr Loïc Faye said that the purified and high quality allergens will be made available to pharmaceutical manufacturers for the development of allergen-specific immunotherapy for the treatment of house dust mite and pollen allergies, and later, food and animal dander allergies.
"As from September 2013 we will be able to meet their requirements in accordance with partnership agreements", Faye added.
With the help of the new production unit, Angany Genetics can rapidly manufacture recombinant allergens that have a structure identical to that of natural allergens with lesser costs.
Angany Genetics scientific director Véronique Gomord said that the production yields will be 5 to 10% of total proteins and may even be as much as 15%.
Angany Genetics was given support by the NBA (Normandy Business Angels).
ANGANY Genetics president and Normandy Business Angels representative Jacques Gerriet said, "Our business angels network was won over both by the scientific expertise of ANGANY Genetics founders, Loïc Faye and Véronique Gomord, and by the ability of their scientific platform to deliver an authentic therapeutic solution to the major healthcare issue currently posed by allergies".